MAX
Company Analysis Innate Pharma S.A.
1. Summary
Advantages
- Price (1.44 $) is less than fair price (1.81 $)
- The stock's return over the last year (-27.82%) is higher than the sector average (-45.46%).
Disadvantages
- Dividends (0%) are below the sector average (0.48%).
- Current debt level 27.91% has increased over 5 years from 6.21%.
- The company's current efficiency (ROE=-162.91%) is lower than the sector average (ROE=100.19%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Innate Pharma S.A. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -10% | -0.6% | -1.9% |
| 90 days | -22.6% | 15.7% | -7.4% |
| 1 year | -27.8% | -45.5% | 17.9% |
IPHA vs Sector: Innate Pharma S.A. has outperformed the "Healthcare" sector by 17.64% over the past year.
IPHA vs Market: Innate Pharma S.A. has significantly underperformed the market by -45.75% over the past year.
Stable price: IPHA is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: IPHA with weekly volatility of -0.53% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (1.44 $) is lower than the fair price (1.81 $).
Price significantly below the fair price: The current price (1.44 $) is 25.7% lower than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-3.62) is lower than that of the sector as a whole (35.81).
P/E vs Market: The company's P/E (-3.62) is higher than that of the market as a whole (-63.23).
5.3. P/BV
P/BV vs Sector: The company's P/BV (16.22) is lower than that of the sector as a whole (189.22).
P/BV vs Market: The company's P/BV (16.22) is lower than that of the market as a whole (72.64).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (11.36) is lower than that of the sector as a whole (149.95).
P/S vs Market: The company's P/S indicator (11.36) is lower than that of the market as a whole (120.26).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-2.3) is higher than that of the sector as a whole (-95.48).
EV/Ebitda vs Market: The company's EV/Ebitda (-2.3) is higher than that of the market as a whole (-81.37).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -3.27% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-3.27%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-12.87%).
6.4. ROE
ROE vs Sector: The company's ROE (-162.91%) is lower than that of the sector as a whole (100.19%).
ROE vs Market: The company's ROE (-162.91%) is lower than that of the market as a whole (23.6%).
6.6. ROA
ROA vs Sector: The company's ROA (-33.51%) is lower than that of the sector as a whole (-8.97%).
ROA vs Market: The company's ROA (-33.51%) is lower than that of the market as a whole (3.23%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-32.33%) is lower than that of the sector as a whole (-0.11%).
ROIC vs Market: The company's ROIC (-32.33%) is lower than that of the market as a whole (8.79%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.48%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Based on sources: porti.ru
